慧俪轻体 WW 深 沪
等待开盘 03-26 09:30:00 美东时间
16.60
-0.810
-4.65%
华盛通- 最 高17.93
- 今 开17.35
- 成交量 22.42万股
- 最 低 16.35
- 昨 收 17.41
- 总市值 1.66亿
- 52周最高 46.949
- 市盈率 静 0.16
- 换手率 2.24%
- 52周最低 16.35
- 委 比 -97.04%
- 总股本 999.65万
- 历史最高 46.949
- 量 比 0.77
- 振 幅 9.08%
- 历史最低 16.35
- 每 手 1
- 风险率 6.06%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多WW International expects $620M–$635M revenue in 2026 as Med+ clinical subscribers surge
Earnings Call Insights: WW International, Inc. (WGHTQ) Q4 2025 Management View Tara Comonte, President and CEO, emphasized the company's transformation following its emergence from Chapter 11, stating...
03-16 23:53
WW International Q4 EPS $(0.58) Beats $(0.62) Estimate, Sales $162.812M Beat $149.099M Estimate
WW International (NASDAQ:WW) reported quarterly losses of $(0.58) per share which beat the analyst consensus estimate of $(0.62) by 6.45 percent. This is a 1550 percent decrease over earnings of $0.04 per share from the
03-16 19:15
Earnings Scheduled For March 16, 2026
Companies Reporting Before The Bell • CytomX Therapeutics (NASDAQ:CTMX) is expe...
03-16 19:11
WW International Sees FY2026 Sales $620.000M-$635.000M vs $633.445M Est
WW International (NASDAQ:WW) sees FY2026 sales of $620.000 million-$635.000 million vs $633.445 million analyst estimate.
03-16 19:09
WW International Q4 revenue falls as behavioral business declines
WW International Q4 revenue falls as behavioral business declines Overview Global weight management firm's Q4 revenue declined 12% yr/yr amid behavioral business headwinds Clinical subscription revenue for Q4 grew 32% yr/yr, driven by GLP-1 medication demand Company projects 2026 revenue of $620 mln
03-16 19:09
WW International, Inc. Q4 2025 Earnings Preview
WW International, Inc. (WW) is scheduled to announce Q4 earnings results on Monday, March 16th, before market open. The consensus EPS Estimate is -$0.40 and the consensus Revenue Estimate is $149.8M M...
03-14 03:11
WW International Releases GLP-1 Results Report Showing That Individuals Who Take GLP-1 Medications And Regularly Engage In Weight Watchers GLP-1 Program Achieved Greater Weight Loss And Better Health Outcomes Than Those Using Medication Alone
Weight Watchers' Med+ members who regularly engaged with their GLP-1 Success Program lost up to 61% more body weight in the first month and 29% more in one year, on average, than those who took medication alone.Med+
03-11 21:08
Weight Watchers Report Finds Integrated GLP-1 Support Drives Significantly Greater Weight Loss Than Medication Alone
Weight Watchers' GLP-1 Success Program shows that combining medication with structured lifestyle support leads to significantly better weight loss and health outcomes. Med+ members lost up to 61% more weight in the first month and nearly 30% more over a year compared to those using medication alone. The program also improves blood pressure, diet quality, and quality of life, while minimizing side effects. Weight Watchers emphasizes a holistic app...
03-11 13:00
Weight Watchers Schedules Fourth Quarter and Full Year 2025 Earnings Conference Call
WW International, Inc. (NASDAQ: WW) plans to release its Q4 and full-year 2025 financial results on March 16, 2026, before market open. A conference call discussing the results will be held at 8:30 a.m. ET on the same day, accessible via webcast from corporate.ww.com. Weight Watchers is a global leader in science-based weight management, offering integrated solutions including GLP-1 medications, technology, and community support. The company has ...
02-27 21:01
Weight Watchers Partners with PVOLVE to Deliver Clinically Validated Strength Workouts to Members in the GLP-1 Era
Weight Watchers partners with PVOLVE to offer exclusive strength and mobility training programs, combining medical expertise with clinically-proven fitness methods. The collaboration provides members with access to PVOLVE's on-demand workouts, starter kits, and specialized classes for midlife women and GLP-1 users, supporting long-term health and longevity.
02-10 14:00
